I-MAB Biopharma and AGC Biologics Partner on Late-Phase Project

Seattle, Dec. 13 (Korea Bizwire) – AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), today announced a new partnership with I-MAB Biopharma (Nasdaq: IMAB). The I-MAB treatment being developed is approaching late-phase clinical trials and AGC Biologics will manufacture the materials at its site in Seattle, while also supporting the launch readiness of [...]